Literature DB >> 11170285

Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia.

H Van Limbergen1, H B Beverloo, E van Drunen, A Janssens, K Hählen, B Poppe, N Van Roy, P Marynen, A De Paepe, R Slater, F Speleman.   

Abstract

Rearrangements of 12p, resulting from deletions or translocations, are common findings in hematologic malignancies. In many cases, these rearrangements target the ETV6 gene (previously called TEL) located at 12p13. Various partner genes have been implicated in the formation of fusion genes with ETV6. These include PDGFRB, JAK2, NTRK3, ABL2, and ABL1, each of which encodes for proteins with tyrosine kinase activity. To date, ETV6/ABL1 transcripts have been detected in only four patients with a leukemic disorder. Here, we describe one adult with chronic myeloid leukemia and a child with T-cell acute lymphocytic leukemia with ETV6/ABL1. Molecular cytogenetic analysis confirmed that formation of an ETV6/ABL1 fusion in these patients required at least three chromosomal breaks and showed that each of these translocations is the result of a complex chromosomal rearrangement. Molecular analysis showed the presence of two fusion transcripts in both patients as the result of alternative splicing, questioning the suggested role of these transcripts in the lineage specificity. Clinical findings of these patients were compared to those of previously reported cases, and the possible clinical and biological similarities between ETV6/ABL1 and other fusion genes leading to increased tyrosine kinase activity are discussed. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170285

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  19 in total

1.  ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition.

Authors:  Fabiana Perna; Omar Abdel-Wahab; Ross L Levine; Suresh C Jhanwar; Kazunori Imada; Stephen D Nimer
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

2.  A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).

Authors:  Satu Mustjoki; Sari Hernesniemi; Auvo Rauhala; Marketta Kähkönen; Anders Almqvist; Tuija Lundán; Kimmo Porkka
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

3.  RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations.

Authors:  Koiti Inokuchi; Satoshi Wakita; Tsuneaki Hirakawa; Hayato Tamai; Norio Yokose; Hiroki Yamaguchi; Kazuo Dan
Journal:  Int J Hematol       Date:  2011-08-24       Impact factor: 2.490

Review 4.  The molecular basis of T cell acute lymphoblastic leukemia.

Authors:  Pieter Van Vlierberghe; Adolfo Ferrando
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 5.  The genetics and mechanisms of T cell acute lymphoblastic leukaemia.

Authors:  Laura Belver; Adolfo Ferrando
Journal:  Nat Rev Cancer       Date:  2016-07-25       Impact factor: 60.716

6.  Cryptic ETV6-ABL1 Fusion and MLL2 Truncation Revealed by Integrative Clinical Sequencing in Multiply Relapsed Acute Lymphoblastic Leukemia.

Authors:  Nikhil P Mankuzhy; Emily Walling; Bailey Anderson; Rajen Mody
Journal:  J Pediatr Hematol Oncol       Date:  2019-11       Impact factor: 1.289

7.  A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.

Authors:  Ryan P Million; Nari Harakawa; Sergei Roumiantsev; Lyuba Varticovski; Richard A Van Etten
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

8.  Characterization of leukemias with ETV6-ABL1 fusion.

Authors:  Marketa Zaliova; Anthony V Moorman; Giovanni Cazzaniga; Martin Stanulla; Richard C Harvey; Kathryn G Roberts; Sue L Heatley; Mignon L Loh; Marina Konopleva; I-Ming Chen; Olga Zimmermannova; Claire Schwab; Owen Smith; Marie-Joelle Mozziconacci; Christian Chabannon; Myungshin Kim; J H Frederik Falkenburg; Alice Norton; Karen Marshall; Oskar A Haas; Julia Starkova; Jan Stuchly; Stephen P Hunger; Deborah White; Charles G Mullighan; Cheryl L Willman; Jan Stary; Jan Trka; Jan Zuna
Journal:  Haematologica       Date:  2016-05-26       Impact factor: 9.941

Review 9.  The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia.

Authors:  Francesca Gianni; Laura Belver; Adolfo Ferrando
Journal:  Cold Spring Harb Perspect Med       Date:  2020-03-02       Impact factor: 6.915

Review 10.  Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.

Authors:  Ashleigh R Poh; Robert J J O'Donoghue; Matthias Ernst
Journal:  Oncotarget       Date:  2015-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.